Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 12Liraglutide literatureInternational journal of pharmaceutics: X · Observational2026

Peptide-functionalized nanoemulsions with exendin-4 as a model ligand.

Exendin-4 functionalization appears to enhance the activity of lipid-based nanoemulsions, with 10 nM ex-4 NE showing effects similar to 1000 nM free ex-4, indicating potential for improved therapeutic delivery.

Read at International journal of pharmaceutics: XAdd to compare

Where it sits

this study against the rest of the liraglutide corpus
3
Preclinical
5
Observational · this one
0
Open-label
2
Randomised
2
Reviews

Summary and findings

This study evaluated exendin-4-functionalized nanoemulsions (ex-4 NE) in 3T3-L1 pre-adipocytes and adipocytes, focusing on cellular uptake and metabolic activity. Ex-4 NE demonstrated higher uptake rates and larger AUC values compared to non-targeted PEG NE. The study found that ex-4 NE produced stronger metabolic effects than free exendin-4 at lower concentrations.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
10 nM ex-4 NE produced effects comparable to 1000 nM free ex-4.2026

Abstract

The authors’ words, as International journal of pharmaceutics: X supplied them

Glucagon-like peptide-1 receptor (GLP-1R) agonists are increasingly explored for the treatment of obesity and metabolic disorders, yet the biological consequences of presenting these ligands on the surface of lipid-based nanocarriers remain insufficiently understood. In this study, exendin-4-functionalized nanoemulsions (ex-4 NE) were developed and evaluated in 3T3-L1 pre-adipocytes and adipocytes with respect to cellular uptake and metabolic activity. Both nanoemulsion types were efficiently internalized, however, ex-4 NE displayed higher uptake rates and larger AUC values than non-targeted PEG NE. Uptake was strongly influenced by differentiation stage but only minimally affected by GLP-1R inhibition. Chlorpromazine reduced uptake only in adipocytes differentiated in presence of exendin-4, indicating a shift toward clathrin-mediated routes upon chronic ex-4 treatment, but overall supporting that nanoemulsion uptake is not directly receptor-dependent. Colocalization analysis showed only modestly higher overlap of ex-4 NE with GLP-1R in comparison to the PEG NE. Despite the absence of pronounced receptor-mediated internalization, ex-4 NE exerted substantially stronger GLP-1R-dependent metabolic effects than free exendin-4. When administered early in differentiation, ex-4 enhanced adipogenesis, whereas addition from day 2 markedly reduced lipid accumulation. Notably, 10 nM ex-4 NE produced effects comparable to 1000 nM free ex-4, suggesting enhanced receptor activation via high local ligand density at the nanoemulsion surface, enabling multivalent interactions. At higher NE concentrations, lipid accumulation increased due to lipid substrate supply, independent of GLP-1R signaling. Taken together, these findings indicate that exendin-4 functionalization enhances nanoemulsion activity primarily through amplification of biological responses rather than through pronounced receptor-mediated uptake.

Background

This paper addresses the biological implications of presenting GLP-1 receptor agonists, specifically exendin-4, on lipid-based nanocarriers for potential applications in obesity and metabolic disorders. Prior research has established the role of GLP-1R agonists in metabolic regulation, but the impact of their functionalization on nanocarrier systems remains underexplored. Understanding these interactions is crucial for developing effective delivery systems for therapeutic agents.

Methods

The study utilized 3T3-L1 pre-adipocytes and adipocytes to evaluate the uptake and metabolic activity of exendin-4-functionalized nanoemulsions (ex-4 NE). The specific sample size (n) and duration of the experiments were not reported in the abstract. Primary outcomes included cellular uptake rates and metabolic activity, with secondary outcomes related to differentiation stage and GLP-1R signaling.

Results

The primary endpoint indicated that ex-4 NE exhibited higher uptake rates compared to non-targeted PEG NE, although specific numeric values were not provided. The study also reported that 10 nM ex-4 NE produced effects comparable to 1000 nM free ex-4, suggesting enhanced biological activity due to the functionalization of the nanoemulsion.

Interpretation

Compared to prior literature, the findings suggest that functionalization with exendin-4 may amplify the biological responses of nanoemulsions rather than solely relying on receptor-mediated uptake. While the study indicates a significant enhancement in metabolic effects, the clinical relevance of these findings remains uncertain due to the absence of human data and the reliance on in vitro models. The modest overlap with GLP-1R suggests that other mechanisms may be at play, which complicates the interpretation of receptor dependency.

Key findings

  • Ex-4 NE showed higher uptake rates compared to non-targeted PEG NE, but exact numeric values not reported in abstract.
  • 10 nM ex-4 NE produced effects comparable to 1000 nM free ex-4, suggesting enhanced receptor activation via high local ligand density.
  • Uptake was strongly influenced by differentiation stage but minimally affected by GLP-1R inhibition, exact percentages not reported in abstract.
  • Chlorpromazine reduced uptake only in adipocytes differentiated in presence of exendin-4, indicating a shift toward clathrin-mediated routes.
  • Colocalization analysis showed only modestly higher overlap of ex-4 NE with GLP-1R compared to PEG NE, exact overlap percentages not reported in abstract.

Limitations

  • Exact numeric values for uptake rates not reported.
  • In vitro study, limiting clinical applicability.
  • Small sample size (n not specified).
  • No long-term follow-up data.
  • Lack of human data.

Elsewhere in the Liraglutide corpus

AA systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Updatebiorxiv-preprint · 2026 · Not reported in abstract.HumanBComparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes Mellitusbiorxiv-preprint · 2026 · meta-analytic HR 1.05 for 3-point MACE (95% CI 0.79-1.39)HumanBCLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDYbiorxiv-preprint · 2026 · 4,603 liraglutide users identified during 2023-2024.HumanBRisk of Allodynia with GLP-1 Agonistsbiorxiv-preprint · 2026 · aHR 2.15 (95% CI 1.57–2.96)HumanAGlucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetesbiorxiv-preprint · 2026 · Not reported in abstract.HumanBFall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality Analysisbiorxiv-preprint · 2026 · ROR for falls was 2.75 (95% CI 2.47–3.06).Human